Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAtrack
NCT06479187Phase 4Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by Brigham and Women's Hospital. Primary endpoint: Proportion of patients with residual PSMA-avid disease on 18F-rhPSMA7.3 PSMA PET at 6 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06479187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479187.